CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs ...
1hon MSN
Dragons' Den for doctors: this competition takes scientists' pitches on how to improve health care
From AI innovations to new medical devices, a research competition at St. Michael's Hospital aims to bring to life ideas that ...
Asianet Newsable on MSN
CRMD Stock Is The Talk Of The Town Today: What’s The Latest 2025 Revenue Forecast?
CorMedix said it was raising its fiscal 2025 pro forma net revenue guidance to at least $375 million. The company said the ...
CorMedix CRMD has experienced significant growth in 2025, fueled by the strong uptake of the company’s lead marketed drug, ...
Company announces positive first-in-human study results, the close of a $6.9 million Series A financing, and FDA approval of ...
CRMD, CELC, RANI, and RAPT are pushing aggressively to the upside on Monday. Here's what is driving these four biotech stocks ...
21h
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
Based on the current sales trend for DefenCath as well as the performance of the recently acquired Melinta portfolio, CorMedix is increasing its full-year 2025 pro forma net revenue guidance from the ...
CorMedix surged on strong DefenCath sales and a Melinta acquisition. I maintain a Sell rating on CRMD stock, citing ...
2don MSN
Seriously-ill baby has eight surgeries in as many months as parents say 'we are not giving up'
Beautiful eight-month-old Hadley Shaw is fighting for his life in the Paediatric Intensive Care Unit at Birmingham Children’s ...
Palliative care is essential for quality of life in chronic illness, urging all doctors to embrace compassionate care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback